Microbot Medical expects FDA 510(k) decision for LIBERTY System in Q3 2025; hires sales ops head

Microbot Medical Inc.

Added Michael Lytle as head of Sales Operations & Analytics to strengthen pre-launch infrastructure.
FDA 510(k) decision now expected in Q3 2025, remaining within original review window.
Projected U.S. launch of LIBERTY Endovascular Robotic System remains on track for Q3 2025.
CEO Harel Gadot stated confidence in FDA process and commercial readiness.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.